Ron Weitzman is a seasoned clinical development executive with over 20 years of experience advancing oncology therapies across solid tumors and hematologic malignancies. He has led the development of small molecules, cytotoxic agents, and monoclonal antibodies, contributing to multiple successful INDs, NDAs, and MAAs. His leadership has guided complex global trials from Phase I through III, including pivotal roles in the development of Avastin, Tasigna, and cabozantinib. Ron’s strategic acumen in regulatory engagement, clinical trial design, and cross-functional team leadership has made him a trusted voice in oncology drug development, supporting sponsors through FDA and EMA interactions and regulatory milestones.